Sulfonyl amino cyclic derivatives and use thereof

Details Sulfonyl amino cyclic derivatives and use thereof Sulfonyl amino cyclic derivatives and use thereof

2011-07-05

2011-07-05

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252140, C514S253010, C514S253060, C514S254010, C514S254030, C514S254110, C514S255030, C544S121000, C544S295000, C544S360000, C544S363000, C544S367000, C544S368000, C544S372000, C544S383000

Reexamination Certificate

active

07973039

ABSTRACT:
The present invention is related to derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

REFERENCES:
patent: 5540938 (1996-07-01), Masterson et al.
patent: 0 627 406 (1994-12-01), None
patent: WO 98/48802 (1998-11-01), None
patent: WO 99/55678 (1999-11-01), None
patent: WO 99/67230 (1999-12-01), None
patent: WO 00/12478 (2000-03-01), None
patent: WO 01/45698 (2001-06-01), None
patent: WO 01/47920 (2001-07-01), None
patent: WO 01/83461 (2001-11-01), None
patent: WO 02/028866 (2002-04-01), None
patent: WO 02/080897 (2002-10-01), None
patent: WO 03/068230 (2003-08-01), None
patent: WO 03/070711 (2003-08-01), None
patent: WO 2004/006926 (2004-01-01), None
patent: WO 2004/028521 (2004-04-01), None
patent: WO 2004/043965 (2004-05-01), None
International Search Report issued in International Application No. PCT/EP2005/056910, dated Apr. 5, 2006, 2 pages.
Written Opinion of the International Searching Authority issued International Application No. PCT/EP2005/056910, dated Apr. 5, 2006, 5 pages.
International Preliminary Report on Patentability issued in International Application No. PCT/EP2005/056910, dated Jun. 26, 2007, 6 pages.
Communication pursuant to Article 94(c) EPC, issued in European Application No. 05 826 371.6-2101, dated Mar. 5, 2009, 2 pages.
Basha, A., et al., “Addition of Organometallic Reagents toN-Glycosyl Nitrones. Enantioselective Syntheses of (+)-(R)- and (−)-(S)-Zileuton,”J. Org. Chem., 59(20): 6103-6106 (1994).
Belvisi, M., et al., “Review: The Role of Matrix Metalloproteinases (MMPs) in the Pathophysiology of Chronic Obstructive Pulmonary Disease (COPD): A Therapeutic Role for Inhibitors of MMPs?,”Inflammation Research, 52: 95-100 (2003).
Bieber, L., et al., “Mild and Efficient Synthesis of Propargylamines by Copper-catalyzed Mannich Reaction,”Tetrahedron Letters, 45(45): 8281-8283 (2004).
Bleicher, L., et al., “A Practical and Efficient Synthesis of the Selective Neuronal Acetylcholinegated Ion Channel Agonist (S)-(−)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate (SIB-1508Y),”J. Org. Chem., 63(4): 1109-1118 (1998).
Brenner, E., et al., “Nickel-catalysed SelectiveN-arylation orN,N1-diarylation of Secondary Diamines,”Tetrahedron, 58(34): 6913-6924 (2002).
Clark, I., et al., “Metalloproteinases: Their Role in Arthritis and Potential as Therapeutic Targets,”Expert Opin. Ther. Targets, 7(1): 19-34 (2003).
Cossy, J., et al., “Synthesis of ML-3000, an Inhibitor of Cyclooxygenase and 5-Lipoxygenase,”J. Org. Chem., 62(23): 7900-7901 (1997).
Doherty, T., et al., “Therapeutic Developments in Matrix Metalloproteinase Inhibition,”Expert Opin. Ther. Patents, 12(5): 665-707 (2002).
Dupont, G., et al., “Étude de Quelques Monodérivés du Butyne-2 diol-1,4,”Bulletin de la Societe Chimique de France, pp. 816-820 (1954).
Fingleton, B., et al., “Matrix Metalloproteinase Inhibitors for Cancer Therapy: The Current Situation and Future Prospects,”Expert Opin. Ther. Targets, 7(3): 385-397 (2003).
Galis, Z., et al., “Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly,”Circulation Research, 90: 251-262 (2002).
Gómez, C., et al., “Functionalised Propargyllithium Reagents,”Tetrahedron, 53(50), 17201-17210 (1997).
Henrotin, Y., et al., “The Inhibition of Metalloproteinases to Treat Osteoarthritis: Reality and New Perspectives,”Expert Opin. Ther. Patents, 12(1): 29-43 (2002).
Hooper, N., et al., “Membrane Protein Secretases,”Biochem. J., 321: 265-279 (1997).
Horstmann, S., et al., “Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients,”Stroke, 34(9): 2165-2172 (2003).
Ingman, T., et al., “Matrix Metalloproteinases and Their Inhibitors in Gingival Crevicular Fluid and Saliva of Periodontitis Patients,”Journal of Clinical Periodontology, 23: 1127-1132 (1996).
Kiritsy, J., et al., “Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SVN-(4-Substituted phenyl)piperazinoacethydrazones,”Journal of Medicinal Chemistry, 21(12): 1301-1307 (1978).
Knight, C., et al., “A Novel Coumarin-labelled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases,”Federation of European Biochemical Societies Letters, 296(3): 263-266(1992).
Koller, M., et al., “278. Zum Mechanismus de α-Alkinon-Cyclisierung: Synthese and Thermolyse von 1-(1-Methylcyclopentyl)[3-13C]prop-2-inon,”Helvetica Chimica Acta, 66(8): 2760-2768 (1983).
Krishna, G., et al., “New Therapies for Chronic Obstructive Pulmonary Disease,”Expert Opin. Investig. Drugs, 13(3): 255-267 (2004).
Leppert, D., et al., “Matrix Metalloproteinases: Multifunctional Effectors of Inflammation in Multiple Sclerosis and Bacterial Meningitis,”Brain Research Reviews, 36: 249-257 (2001).
Liu, M., et al., “Association of Increased Expression of Macrophage Elastase (Matrix Metalloproteinases 12) With Rheumatoid Arthritis,”Arthritis&Rheumatism, 50(10): 3112-3117 (2004).
Makrakis, E., et al., “Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Plasma/serum and Urine of Women During Term and Threatened Preterm Labor: A Clinical Approach,”The Journal of Maternal-Fetal and Neonatal Medicine, 14(3): 170-176 (2003).
Nugent, W., et al., “Cyclization of Diacetylenes toE,EExocyclic Dienes. Complementary Procedures Based on Titanium and Zirconium Reagents,”J. Am. Chem. Soc., 109(9): 2788-2796 (1987).
Opdenakker, G., et al., “Functional Roles and Therapeutic Targeting of Gelatinase B and Chemokines in Multiple Sclerosis,”The Lancet Neurology, 2: 747-756 (2003).
Peterson, J., et al., “Matrix Metalloproteinasse Inhibitor Development and the Remodeling of Drug Discovery,”Heart Failure Reviews, 9: 63-79 (2004).
Skiles, J., et al., “The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors,”Current Medicinal Chemistry, 8(4): 425-474 (2001).
Skotnicki, J., et al., “Design Strategies for the Identification of MMP-13 and TACE Inhibitors,”Current Opinion in Drug Discovery&Development, 6(5): 742-759 (2003).
Swanson, D., et al., “Identification and Biological Evaluation of 4-(3-Trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-Trifluoromethylpyridin-2-61)amide, a High Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist,”J. Med. Chem., 48(6): 1857-1872 (2005).
Visse, R., et al., “Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry,”Circulation Research, 92: 827-839 (2003).
Vos, C., et al., “Matrix Metalloproteinase-12 is Expressed in Phagocytotic Macrophages in Active Multiple Sclerosis Lesions,”Journal of Neuroimmunology, 138: 106-114 (2003).
Wada, C., et al., “Phenoxyphenyl SulfoneN-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors,”J. Med. Chem., 45(1): 219-232 (2002).
Wustrow, D., et al., “Coupling of Arylboronic Acids With a Partially Reduced Pyridine Derivative,”Synthesis, pp. 993-995 (Nov. 1991).
Zhao, S., et al., “Synthesis of Arylpiperazines via Palladium-catalyzed Aromatic Amination Reaction With Unprotected Piperazines,”Tetrahedron Letters, 37(26): 4463-4466 (1996).

Affiliated with

Also associated with

Rating

Sulfonyl amino cyclic derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonyl amino cyclic derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonyl amino cyclic derivatives and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2633895